Trial intelligence / Profile preview

QL-007 + TDF in Naive Chronic Hepatitis B

NCT04157699Phase 2Unknown

Sponsor
Qilu Pharmaceutical
Start
Jul 2019
Primary completion
Dec 2020
Modality
Small Molecules
Countries
1
01

Overview

A Phase 2 trial of QL-007 in Chronic Hepatitis B (CHB), sponsored by Qilu Pharmaceutical. Status: unknown.

02

Drugs

QL-007
03

Conditions

Chronic Hepatitis B (CHB)

Beyond the preview

Go deeper on NCT04157699.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT04157699.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call